(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione
- CAS No.
- 760173-05-5
- Chemical Name:
- (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione
- Synonyms
- BIA 5-453;EtaMicastat;(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione;2H-Imidazole-2-thione, 5-(2-aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-
- CBNumber:
- CB02484710
- Molecular Formula:
- C14H15F2N3OS
- Molecular Weight:
- 311.35
- MDL Number:
- MFCD16619338
- MOL File:
- 760173-05-5.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| ETAMICASTAT 95.00% | INB0001475 | 5MG | $502.19 |
| Boiling point | 435.3±55.0 °C(Predicted) |
|---|---|
| Density | 1.44 |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| pka | 11.73±0.70(Predicted) |
| form | powder |
| color | white to beige |
| FDA UNII | 9X96V6DBU4 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione Chemical Properties,Uses,Production
Uses
Etamicastat (BIA 5-453) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM[1]. Etamicastat can be used in the research of cardiovascular diseases[2].
Biological Activity
Orally active, potent, reversible and peripherally selective dopamine-β-hydroxylase (DBH) inhibitor.
Etamicast at (BIA 5-453) is an orally active, potent, reversible and peripherally selective dopamine-β-hydroxylase (DBH) inhibitor th at reduces both systolic (SBP) and diastolic (DBP) blood pressure.
in vivo
Etamicastat (100 mg/kg; administered intraperitoneally) leads to a significant reduction of noradrenaline levels in heart with concomitant increasing in dopamine levels[1].
Etamicastat (50 mg/kg; a single oral administration) exhibits moderate oral bioavailability (64%), Cmax (4.9 nM), and terminal elimination half-lives (T1/2=3.7 h) in male Wistar rats[1].
| Animal Model: | NMRi mice[1] |
| Dosage: | 100 mg/kg |
| Administration: | Administered intraperitoneally |
| Result: | Led to a significant reduction of noradrenaline levels (36% control) in heart with concomitant increasing in dopamine levels (850% of control). |
| Animal Model: | Male Wistar rats[1] |
| Dosage: | 50 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Orally administered with at a dose volume of 10 mL/kg |
| Result: | Oral bioavailability (64%), Cmax (4.9 nM), and (T1/2=3.7 h). |
References
[1] Loureiro AI, et al. Etamicastat, a new dopamine-?-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol. 2014 Oct 5;740:285-94. DOI:10.1016/j.ejphar.2014.07.027
[2] ManuelVaz-da-Silva, et al. Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. IJC Metabolic & Endocrine. 2015 Ju
(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione Preparation Products And Raw materials
Raw materials
Preparation Products
(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49975 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32435 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39035 | 58 |
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 19962 | 58 |
| BOC Sciences | -- | info@bocsci.com | USA | 0 | 65 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29641 | 58 |
| Merck KGaA | 21-20338288 | ordercn@merckgroup.com | China | 6394 | 58 |
| Adooq Bioscience LLC | 400-025-6535 | sales@adooq.cn | China | 6215 | 58 |
| Supplier | Advantage |
|---|---|
| CONIER CHEM AND PHARMA LIMITED | 58 |
| TargetMol Chemicals Inc. | 58 |
| TargetMol Chemicals Inc. | 58 |
| TargetMol Chemicals Inc. | 58 |
| BOC Sciences | 65 |
| TargetMol Chemicals Inc. | 58 |
| Merck KGaA | 58 |
| Adooq Bioscience LLC | 58 |
View Lastest Price from (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
![]() |
2025-08-21 | Etamicastat
760173-05-5
|
US $2420.00-3180.00 / mg | 10g | TargetMol Chemicals Inc. | |||
![]() |
2025-07-18 | Etamicastat
760173-05-5
|
US $2420.00-3180.00 / mg | 10g | TargetMol Chemicals Inc. |
-

- Etamicastat
760173-05-5
- US $2420.00-3180.00 / mg
- TargetMol Chemicals Inc.
-

- Etamicastat
760173-05-5
- US $2420.00-3180.00 / mg
- TargetMol Chemicals Inc.




